Upcoming Discussion on Financial Results at Beyond Air
Beyond Air, Inc. (NASDAQ: XAIR) is set to present its financial results for the fiscal fourth quarter and full year, which concluded on March 31, 2025. The company, focused on innovative medical devices and biopharmaceuticals, employs nitric oxide (NO) to enhance patient care. This important update is scheduled for June 17, 2025, with the management team hosting a conference call and webcast at 4:30 PM Eastern Time.
Details of the Conference Call
On the specified date, stakeholders can join the discussions via a dial-in option:
Conference Call Information
Domestic: 1-877-407-0784
International: 1-201-689-8560
Conference ID: 13753945
Participants can also listen to the event through a dedicated webcast available on the company's website. An online replay will commence an hour following the live call, ensuring that all interested parties have access to this pivotal information at their convenience.
Who is Beyond Air?
About the Company
Beyond Air is a pioneering firm dedicated to the development of medical devices and biopharmaceuticals that utilize both endogenous and exogenous nitric oxide to address various health challenges. The company has achieved FDA approval and a CE Mark for its primary system, LungFit® PH, specifically designed for treating newborns experiencing hypoxic respiratory failure.
Advancements and Future Directions
Beyond Air is committed to the advancement of its innovative LungFit systems, which are currently undergoing clinical trials for severe lung infections, including viral pneumonia and nontuberculous mycobacteria. The company is also collaborating with The Hebrew University of Jerusalem to explore treatment options for autism spectrum disorders and other neurological complications.
An additional branch of the company, Beyond Cancer, Ltd., is invested in pioneering research focusing on ultra-high concentrations of nitric oxide through a specialized delivery system. This pre-clinical approach aims to tackle specific solid tumors, showcasing the company's broad commitment to leveraging nitric oxide's therapeutic potential.
Continuing Innovations in Patient Care
Through its various initiatives and research, Beyond Air is at the forefront of developing solutions that not only address respiratory issues but also target life-threatening diseases. By exploring the extensive applications of nitric oxide, Beyond Air is determined to enhance treatment options and improve the quality of life for patients globally.
Commitment to Safety and Efficacy
The company remains dedicated to advancing its product candidates by ensuring the highest standards of safety and efficacy. While the path to regulatory approval can be challenging, Beyond Air’s proactive approach in clinical trials underscores their commitment to bringing innovative treatments to market.
Frequently Asked Questions
What is Beyond Air focusing on in its upcoming conference call?
The conference call will address Beyond Air's financial results and ongoing efforts to improve patient treatments using nitric oxide.
How can I access the conference call?
Individuals can participate through a dial-in number or via the webcast available on the company's website.
What medical areas does Beyond Air focus on?
Beyond Air concentrates on respiratory illnesses, neurological disorders, and solid tumors through nitric oxide therapies.
What recent developments has Beyond Air achieved?
The company received FDA approval for LungFit® PH, as well as CE Mark certification, enhancing its credibility in the market.
Who can I contact for more information?
For further inquiries, Corey Davis from LifeSci Advisors is available at (212) 915-2577 or via email.
